Discovery of a potent and orally bioavailable CCR2 and CCR5 dual antagonist

ACS Medicinal Chemistry Letters

Volumn 1, Issue 1, 2010, Pages 14-18

  Pasternak, Alexander ^a   Goble, Stephen D ^a   Struthers, Mary ^a   Vicario, Pasquale P ^a   Ayala, Julia M ^a   Di Salvo, Jerry ^a   Kilburn, Ruth ^a   Wisniewski, Thomas ^a   Demartino, Julie A ^a   Mills, Sander G ^a   Yang, Lihu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CCR2; CCR5; chemokine; dual antagonist

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DELAYED RECTIFIER POTASSIUM CHANNEL; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; HUMAN; HYDROGENOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

EID: 77956621678     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml900009d     Document Type: Article

References (34)

1. Mackay, C. R. Chemokines: Immunology's high impact factors Nat. Immunol. 2001, 2, 95-101
2. Charo, I. F.; Myers, S. J.; Herman, A.; Franci, F.; Connolly, A. J.; Coughlin, S. R. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2752-2756
3. Dawson, J.; Miltz, W.; Mir, A. K.; Weissner, C. Targeting monocyte chemoattractant protein-1 signalling in disease Expert Opin. Ther. Targets 2003, 7 (1) 35-48
4. Feria, M.; Diaz-Gonzalez, F. The CCR2 receptor as a therapeutic target Expert Opin. Ther. Pat. 2006, 16, 49-57
5. Gong, J.-H.; Ratkay, L. G.; Waterfield, J. D.; Clark-Lewis, I. An antagonist of monocyte chemoattractant Protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model J. Exp. Med. 1997, 186 (1) 131-137
6. Izikson, L.; Klein, R. S.; Luster, A. D.; Weiner, H. L. Targeting monocyte recruitment in CNS autoimmune disease Clin. Immunol. 2002, 102 (2) 125-131
7. Gosling, J.; Slaymaker, S.; Gu, L.; Tseng, S.; Zlot, C. H.; Young, S. G.; Rollins, B. J.; Charo, I. F. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B J. Clin. Invest. 1999, 103, 773-778
8. Donnelly, L. E.; Rogers, D. F. Therapy for chronic obstructive pulmonary disease in the 21st century Drugs 2003, 63, 1973-1998
9. Mellado, M.; deAna, A. M.; Gomez, L.; Martinez-A, C.; Rodriguez-Frade, J. M. Chemokine receptor 2 blockade prevents asthma in a cynomolgus monkey model J. Pharmacol. Exp. Ther. 2008, 324, 769-775
10. Tamura, Y.; Sugimoto, M.; Muruyama, T.; Ueda, Y.; Kanamori, H.; Ono, K.; Ariyasu, H.; Akamizu, T.; Kita, T.; Yokode, M.; Arai, H. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice Arterioscler. Thromb. Vasc. Biol. 2008, 28, 2195-2201
11. Weisberg, S. P.; Hunter, D.; Huber, R.; Lemieux, J.; Slaymaker, S.; Vaddi, K.; Charo, I.; Leibel, R. L.; Ferrante, A. W., Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding J. Clin. Invest. 2006, 116 (1) 115-124
12. Abbadie, C.; Lindia, J. A.; Cumiskey, A. M.; Peterson, L. B.; Mudgett, J. S.; Bayne, E. K.; DeMartino, J. A.; MacIntyre, D. E.; Forrest, M. J. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2 Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (13) 7947-7952
13. Yang, L.; Zhou, C.; Guo, L.; Morriello, G.; Butora, G.; Pasternak, A.; Parsons, W. H.; Mills, S.; MacCoss, M.; Vicario, P. P.; Zweerink, H.; Ayala, J. M.; Goyal, S.; Hanlon, W. A.; Cascieri, M. A.; Springer, M. S. Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists Bioorg. Med. Chem. Lett. 2006, 16 (14) 3735-3739
14. Pasternak, A.; Marino, D.; Vicario, P. P.; Ayala, J. M.; Cascierri, M. A.; Parsons, W. H.; Mills, S. G.; MacCoss, M.; Yang, L. Novel, orally bioavailable -aminoamide CC chemokine receptor 2 (CCR2) antagonists J. Med. Chem. 2006, 49 (16) 4801-4804
15. Yang, L.; Butora, G.; Jiao, R. X.; Pasternak, A.; Zhou, C.; Parsons, W. H.; Mills, S. G.; Vicario, P. P.; Ayala, J. M.; Cascieri, M. A.; MacCoss, M. Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists J. Med. Chem. 2007, 50 (11) 2609-2611
16. Butora, G.; Jiao, R.; Parsons, W. H.; Vicario, P. P.; Jin, H.; Ayala, J. M.; Cascieri, M. A.; Yang, L. 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2 Bioorg. Med. Chem. Lett. 2007, 17 (13) 3636-3641
17. Pasternak, A.; Goble, S. D.; Vicario, P. P.; Di Salvo, J.; Ayala, J. M.; Struthers, M.; DeMartino, J. A.; Mills, S. G.; Yang, L. Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists Bioorg. Med. Chem. Lett. 2008, 18 (3) 994-998
18. Xia, M.; Sui, Z. Recent developments in CCR2 antagonists Expert Opin. Ther. Pat. 2009, 19 (3) 295-303
19. Pease, J. E.; Horuk, R. Chemokine receptor antagonists: Part 1 Expert Opin. Ther. Pat. 2009, 19 (1) 39-58
20. Kalinowska, A.; Losy, J. Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases Expert Opin. Invest. Drugs 2008, 17 (9) 1267-1279
21. Vergunst, C. E.; Gerlag, D. M.; Lopatinskaya, L.; Klareskog, L.; Smith, M. D.; van der Bosch, F.; Dinant, H. J.; Lee, Y.; Wyant, T.; Jacobsen, E. W.; Baeten, D.; Tak, P. P. Modulation of CCR2 in Rheumatoid Arthritis. A double blind, randomized, placebo-controlled clinical trial Arthritis Rheum. 2008, 58 (7) 1931-1939
22. Beaulieu, A.; Hasler, F.; Martin Mola, E.; Pavelka, K.; DeMartino, J.; Struthers, M. The efficacy and safety of a CCR2 receptor antagonist in the treatment of rheumatoid arthritis Ann. Rheum. Dis. 2006, 65 (Suppl. 2) 175
23. Davidson, M. Abstract 874: MNL1202, a novel CCR2 antagonist, decreases C-reactive protein in patients at risk for atherosclerotic cardiovascular disease in a double blind placebo controlled study Circulation 2007, 116 (Suppl.) 171
24. Cavero, I.; Mestre, M.; Guillon, J.-M.; Crumb, W. Drugs That Prolong QT Interval as an Unwanted Effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias Expert Opin. Pharmacother. 2000, 1, 947-973
25. Kr potassium channel Cell 1995, 81, 299-307
26. 2A receptor antagonists J. Med. Chem. 2001, 44, 1603-1614
27. Woiwode, T. F.; Rose, C.; Wandless, T. J. A simple and efficient method for the preparation of hindered alkyl-aryl ethers J. Org. Chem. 1998, 63, 9594-9596
28. Wright, S. W.; Hageman, D. L.; Wright, A. S.; McClure, L. D. Convenient preparations of t-butyl esters and ethers from t-butanol Tetrahedron Lett. 1997, 38 (42) 7345-7348
29. Wustrow, D. J.; Wise, L. D. Coupling of arylboronic acids with a partially reduced pyridine derivative Synthesis 1991, 993-995
30. Sheehan, J. C.; Tulis, R. W. Oxidation of cyclic amines with ruthenium tetroxide J. Org. Chem. 1974, 39 (15) 2264-2267
31. The Merck process chemistry group devised a synthesis of the (4 R)-carboxyphenyl-(3 S)-methyl piperidine subunit starting from pure methyl (S)-(+)-3-hydroxy-2-methylpropionate. They also devised a synthesis of the cis -(3 R,1 S)-cyclopentane core also using starting materials of known absolute stereochemistry. This improved synthesis will be described elsewhere.
32. Wisniewski, T.; Bayne, E.; Flanagan, J.; Shao, Q.; Wnek, R.; Matheravidathu, S.; Fischer, P.; Forrest, M. J.; Peterson, L.; Song, X.; Yang, L.; DeMartino, J. A.; Struthers, M. Assessment of chemokine receptor function on monocytes in whole blood: in vitro and ex vivo evaluation of a CCR2 antagonist. J. Immunol. Methods 2010, 352, 101 - 110
33. 1/2 of 5 h at 37 °C for CCR2.
34. Compound 22 was dosed orally in 5 rhesus at 2 mg/kg and plasma concentration of 22 and MCP-1 whole blood monocyte shape change was determined at various time points postdosing (6, 24, 36, 48, 72 h). % inhibition shape change was determined by comparing postdose values to predose values in the same animals. See also ref 32.